AdvanCell
Signal active
Organization
Contact Information
Overview
AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment.
About
Industries
Biotechnology, Pharmaceutical, Clinical Trials, Oncology
Founded
2019
Employees
11-50
Headquarters locations
Sydney, New South Wales, Australia, Oceania
Social
N/A
Profile Resume
AdvanCell headquartered in Sydney, New South Wales, Australia, Oceania, operates in the Biotechnology, Pharmaceutical, Clinical Trials, Oncology sector. The company focuses on Biotechnology and has secured $465.8M in funding across 32 round(s). With a team of 11-50 employees, AdvanCell is actively contributing to advancements in Biotechnology. Their latest funding round, Grant - AdvanCell, raised $2.1M. Discover more about their projects, partnerships, and impact on our platform.
Employees
N/A
Funding Rounds
Funding rounds
2
Investors
1
Lead Investors
0
Total Funding Amount
$14.6M
Details
1
AdvanCell has raised a total of $14.6M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2022 | Early Stage Venture | 12.5M |
Investors
AdvanCell is funded by 5 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| AdvanCell | - | FUNDING ROUND - AdvanCell | 12.5M |
| Morningside Venture Investments | - | FUNDING ROUND - Morningside Venture Investments | 12.5M |
| AdvanCell | - | FUNDING ROUND - AdvanCell | 2.1M |
| NSW Health | - | FUNDING ROUND - NSW Health | 2.1M |
Recent Activity
There is no recent news or activity for this profile.